Pennington Biomedical Research Center

Pennington Biomedical Research Center, a Louisiana State University–affiliated state government research institution, operates as a prime recipient on federal research grants and a prime contractor on Department of Defense biochemistry analysis service contracts, with secondary activity as a subcontractor and sub-recipient on multi-institutional research programs. The center does not compete for set-asides and operates exclusively in full-and-open federal contracting.

Pennington Biomedical specializes in nutrition and metabolism research, including biochemistry and biomarker analysis services that support federal medical research initiatives. On the contract side, the center delivers biochemistry analysis services—analysis of biological samples such as blood and urine to measure nutritional and metabolic biomarkers, vitamin D analysis, and related chemical measurements—through a single-award Indefinite Delivery Contract with the U.S. Army Medical Command valued at $7.8 million and extending through September 2029. Delivery orders issued under this IDC have ranged from $3,260 to $279,712 in value. Representative delivery orders include a $12,881 firm fixed-price order for biochemistry analysis (awarded September 2025, completion September 2026), a $133,365 order for biochemistry analysis support services (awarded September 2024, completion September 2026), and a $20,855 order for 25(OH) vitamin D analysis (awarded May 2023, completion May 2023). Work is performed primarily at the center's Baton Rouge facility and secondarily at the U.S. Army Research Institute of Environmental Medicine in Natick, Massachusetts.

On the grants side, Pennington Biomedical is a prolific recipient of NIH funding. The center holds active project grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung and Blood Institute, the National Institute of Child Health and Human Development, the National Institute on Aging, the National Institute of General Medical Sciences, and the National Institute for Minority Health and Health Disparities, addressing research areas spanning obesity metabolism, adipocyte biology, glucose homeostasis, cardiovascular risk, prenatal nutrition, brown adipose tissue development, and sarcopenic obesity. Recent awards include a $736,602 NHLBI grant for hydrogen sulfide research in heart failure (July 2026, completion March 2031), a $731,916 NIDDK grant for infant energy balance characterization (August 2026, completion April 2031), and a $251,580 NIDDK grant for neural mechanisms of protein preference (April 2026, completion September 2027). The center also received a cooperative agreement from NIDDK for the Louisiana Center for Advancing Underrepresented Scientists Careers (LAUNCHED), a multi-institution program supporting early-stage investigators in obesity and diabetes research. Equipment funding includes an $808,000 NIH Office of the Director grant for a 3T Siemens VIDA MRI system upgrade (August 2025, completion July 2027).

Customer concentration is dominated by NIH. The top five funding sources account for 63% of recent award count: NIDDK (62 awards), general NIH (69 awards), the Army Medical Command (37 awards, $29.2 million combined potential value), the National Institute on Aging (23 awards), and the NIH Office of the Director (16 awards). The Army Medical Command anchors nearly all measurable contract dollars. Across 328 total awards in the source data, 76% are prime awards and 24% are sub-awards. The center completes approximately 15–36 awards per year; 22 awards face ultimate completion within the next twenty-four months, signaling moderate recompete exposure.

Pennington Biomedical operates as a sub-recipient on numerous collaborative research programs, partnering with universities including Adventist Health System, Colorado State University, Duke University, Tufts University, the University of Hawaii, the University of Texas, and others on multi-site clinical trials and observational studies. The center's sub-recipient work encompasses participant enrollment, clinical assessment, biospecimen collection and analysis, data management, and statistical support. Representative sub-grants include work on the CALERIE Legacy Study (a longitudinal aging biology study led by Tufts and Duke), shift worker metabolic health trials (Colorado State), food intake and dietary assessment studies (University of Hawaii and University of Denver), and the RURAL Heart and Lung Study (University of Texas Health Science Center at San Antonio).

On the contract subcontracting side, Pennington Biomedical performs biochemistry analysis and RBC fatty acid analysis as a named subcontractor under larger prime contracts, including work on the RURAL study community engagement and operations (sub to Ma Federal, Inc.). The center also engages in clinical trial support for multi-site studies, performing roles such as participant screening, MRI acquisition and analysis, data collection, and biospecimen processing.

The center's corporate identity reflects its LSU affiliation. While LSU is the parent entity, Pennington Biomedical operates as a distinct research division with its own federal award identity, managing its own facilities, cores (including mass spectrometry, MRI, clinical metabolic assessment, and biorepository resources), and research portfolio. Historically, the center has served as a national leader in human metabolism research, leveraging state-of-the-art clinical measurement capabilities to conduct feeding trials, metabolic phenotyping, and longitudinal cohort studies in obesity, diabetes, cardiovascular disease, and aging. The institutional research infrastructure—including dedicated clinical beds, metabolic chambers, imaging systems, and clinical laboratory capacity—positions the center to support both internal grant-funded research and external collaborative studies requiring in-patient or controlled feeding protocols. Service Contract Inventory captures minimal activity ($0 recorded in SCI invoicing for FY2024), reflecting that Pennington Biomedical's federal revenue derives predominantly from federal grants and research contracts rather than billable service contracts above the reporting threshold.